Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone216-431-9900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.29 million
Profitability
Miscellaneous
Employees75
Next Earnings Date5/8/2019 (Confirmed)
OptionableOptionable
Athersys (NASDAQ:ATHX) Frequently Asked Questions
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) issued its earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company earned $1.51 million during the quarter, compared to analyst estimates of $0.55 million. Athersys had a negative return on equity of 49.25% and a negative net margin of 99.96%. View Athersys' Earnings History.
When is Athersys' next earnings date?
What price target have analysts set for ATHX?
1 equities research analysts have issued 1-year price targets for Athersys' stock. Their predictions range from $8.00 to $8.00. On average, they anticipate Athersys' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 455.6% from the stock's current price. View Analyst Price Targets for Athersys.
What is the consensus analysts' recommendation for Athersys?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athersys.
Has Athersys been receiving favorable news coverage?
Press coverage about ATHX stock has trended somewhat positive on Monday, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Athersys earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include Retrophin (RTRX), Advanz Pharma (CXRXF), ANI Pharmaceuticals (ANIP), MacroGenics (MGNX), Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT), CannTrust (CTST), CannTrust (CNTTF), Athenex (ATNX), Arvinas (ARVN), CymaBay Therapeutics (CBAY), Cara Therapeutics (CARA), ArQule (ARQL), Principia Biopharma (PRNB) and ChemoCentryx (CCXI).
What other stocks do shareholders of Athersys own?
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)
- Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA, Pres, COO & Sec. (Age 53)
- Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)
- Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)
- Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs
Who are Athersys' major shareholders?
Athersys' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Livingston Group Asset Management CO operating as Southport Capital Management (0.02%) and Mercer Global Advisors Inc. ADV (0.02%). Company insiders that own Athersys stock include John J Harrington, Laura K Campbell and William Lehmann Jr. View Institutional Ownership Trends for Athersys.
Which major investors are buying Athersys stock?
ATHX stock was acquired by a variety of institutional investors in the last quarter, including Livingston Group Asset Management CO operating as Southport Capital Management and Mercer Global Advisors Inc. ADV. View Insider Buying and Selling for Athersys.
How do I buy shares of Athersys?
Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of ATHX stock can currently be purchased for approximately $1.44.
How big of a company is Athersys?
Athersys has a market capitalization of $211.45 million and generates $24.29 million in revenue each year. The biopharmaceutical company earns $-24,280,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Athersys employs 75 workers across the globe.
What is Athersys' official website?
How can I contact Athersys?
Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]m.
MarketBeat Community Rating for Athersys (NASDAQ ATHX)
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
